



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	PF168P3
-------	---	----	---	------------------------	---------

Complete if Known

Application Number	10/070,532-Conf. #5548
Filing Date	March 7, 2002
First Named Inventor	Daniel R. Soppet
Art Unit	1647
Examiner Name	C. J. Nichols
Attorney Docket Number	PF168P3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2002/0082202	06-27-2002	Bergsma, et al.	
	AB	US-5,527,676	06-18-1996	Vogelstein, et al.	
	AC	US-5,935,814	08-10-1999	Bergsma, et al.	
	AD	US-6,001,963	12-14-1999	Bergsma, et al.	
	AE	US-6,020,157	02-01-2000	Bergsma, et al.	
	AF	US-6,309,854	10-30-2001	Bergsma, et al.	
	AG	US-6,319,710	11/2001	Olafsdottir, et al.	
	AH	US-6,372,757	04-16-2002	Johns, et al.	

FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)					
CSN	AI	WO-93/09277		05-13-1993	Garvan Inst. Med. Res.		
	AJ	WO-93/11249		06-10-1993	Novo Nordisk, A/S		
	AK	WO-94/05695		03-17-1994	New York University		
	AL	WO-96/05302		02-22-1996	Takeda Chemical Indust.		
	AM	WO-96/34877		11-07-1996	Human Genome Sciences, Inc.		
	AN	WO-99/58533		11-18-1999	SmithKline Beecham		
	AO	WO-00/47284		08-17-2000	SmithKline Beecham		
	AP	WO-01/14555		03-01-2001	Decode Genetics EHF.		
	AQ	WO-01/30991		05-03-2001	Decode Genetics EHF.		
	AR	EP-0 121 352		10-10-1984	The Public Health Laboratory Service Board		
	AS	EP-0 875 566		10-27-1997	SmithKline Beecham		
	AT	EP-0 875 565		11-04-1998	SmithKline Beecham		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CSN	AU	ATCC Catalog of Cell lines and hybridomas, 7th Edition (1992)	
	AV	BURBACH, et al., "The structure of neuropeptide receptors," <i>Eur J Pharmacology</i> , 227(1):1-18 (September 1, 1992)	
	AW	COLMERS, et al., "Effects of neuropeptide Y on the electrical properties of neurons," <i>TINS</i> , 17(9):373-379 (1994)	
CSN	AX	De LECEA, et al., "The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity," <i>Proc. Natl. Acad. Sci. USA</i> , 95:322-327 (January 1998)	

Examiner Signature	<i>C. J. Nichols</i>	Date Considered	10/13/04
--------------------	----------------------	-----------------	----------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	3	Attorney Docket Number	PF168P3
-------	---	----	---	------------------------	---------

Complete if Known

Application Number	10/070,532-Conf. #5548
Filing Date	March 7, 2002
First Named Inventor	Daniel R. Soppet
Art Unit	1647
Examiner Name	C. J. Nichols
Attorney Docket Number	PF168P3

AY	de WEERTH, et al., "Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor," <i>Biochem. Biophys. Res. Comm.</i> , 194:811-818 (1993)	—
AZ	EVA, et al., "Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family," <i>FEBS Lett.</i> , 271(1-2):81-84 (October 1, 1990)	—
BA	FLIER, et al., "Obesity and the hypothalamus: novel peptides for new pathways," <i>Cell</i> , 92:437-440 (February 20, 1998)	—
BB	GEHLERT, et al., "Expression cloning of a human brain neuropeptide Y Y2 receptor," <i>Mol. Pharmacol.</i> , 49:224-228 (1996)	—
BC	GENCIK, et al., "ApoE polymorphisms in narcolepsy," <i>BCM Medical Genetics</i> , 2:9 (August 9, 2001)	—
BD	Genbank Accession No.: R40951 (May 22, 1995)	—
BE	Genbank Accession No.: R55705 (May 22, 1995)	—
BF	Genbank Accession No.: JN0692 (February 23, 1997)	—
BG	Genbank Accession No.: R55704 (May 22, 1995)	—
BH	GeneSeq Accession No.: T51065 (March 13, 1997)	—
BI	GeneSeq Accession No.: W11236 (March 13, 1997)	—
BJ	GeneSeq Accession No.: T13909 (August 27, 1996)	—
BK	GeneSeq Accession No.: R91233 (August 27, 1996)	—
BL	GRÜNDKER, et al., "Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer," <i>Reproductive Biology and Endocrinology</i> , 1:65 (October 7, 2003)	—
BM	HABERT-ORTOLI, et al., "Molecular cloning of a functional human galanin receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 91:9780-9783 (October 1994)	—
BN	HAKANSSON, et al., "Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus," <i>J. Neuroendocrinol.</i> , 11(8):653-663 (August 1999) (Abstract Only)	—
BO	HAWES, et al., "Inhibition of G protein-coupled receptor signaling by expressing of cytoplasmic domains of the receptor," <i>J. Biol. Chem.</i> , 269:15776-15785 (1994)	—
BP	HERZOG, et al., "Cloned human neuropeptide Y receptor couples to two different second messenger systems," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5794-5798 (July 1992)	—
BQ	HERZOG, et al., "Genomic organization, localization, and allelic differences in the gene for the human neuropeptide Y T1 receptor," <i>J. Biol. Chem.</i> , 268(9):6703-6707 (1993)	—
BR	HERZOG, et al., "Molecular Cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: Lack of NPY binding and activation," <i>DNA and Cell Biology</i> , 12:465-471 (1993)	—
BS	HILAIRET, et al., "Hypersensitization of the orexin 1 receptor by the CB1 receptor," <i>The Journal of Biological Chemistry</i> , 278(26):23731-23737 (June 27, 2003)	—
BT	HUNGS, et al., "Hypocretin/orexin, sleep, and narcolepsy," <i>Bioessays</i> , 23:397-408 (2001)	—
BU	International Search Report, Application No. PCT/US00/24518 (January 18, 2001)	—
BV	IRVING, et al., "Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat," <i>Neuroscience Letters</i> , 324:53-56 (May 10, 2002)	—
BW	JAZIN, et al., "A Proposed Bovine Neuropeptide Y (NPY) Receptor cDNA Clone, or Its Human Homologue, Confers Neither NPY Binding Sites Nor NPY Responsiveness on Transfected Cells," <i>Regulatory Peptides</i> , 47:247-258 (1993)	—
BX	LaNOUE, et al., "Abnormal A ₁ adenosine receptor function in genetic obesity," <i>FASEB Journal</i> , 8:72-80 (1994)	—
BY	LARHAMMAR, et al., "The receptor revolution -- multiplicity of G-protein-coupled receptors," <i>Drug Design and Discovery</i> , 9:179-188 (1993)	—
BZ	LARHAMMAR, et al., "Cloning and functional expression of a human neuropeptide Y/Peptide YY receptor of the Y1 type," <i>The Journal of Biological Chemistry</i> , 267(16):10935-10938 (June 5, 1992)	—
Examiner Signature		Date Considered
		10/13/04



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/070,532-Conf. #5548	
			Filing Date	March 7, 2002	
			First Named Inventor	Daniel R. Soppet	
			Art Unit	1647	
			Examiner Name	C. J. Nichols	
Sheet	3	of	3	Attorney Docket Number	PF168P3

CA	LEBO, et al., Cold Spring Harbor Symp. Quant. Biol., 51:169-176 (1986)
CB	LEIBEL, et al., "Strategies for the molecular genetic analysis of obesity in humans," <i>Crit. Rev. Food Sci. and Nutr.</i> , 33(4-5):351-358 (1993)
CC	LUNDELL, et al., "The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous human receptor," <i>PNAS</i> , 93:5111-5115 (1996)
CD	LUTTRELL, et al., "Antagonism of catecholamine receptor signaling by expression of cytoplasmic domains of the receptors," <i>Science</i> , 259:1453-1457 (1993)
CE	MANTZOROS, et al., "Activation of β_3 adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice," <i>Diabetes</i> , 45:909-914 (1996)
CF	MARCHESE, et al., "Two gene duplication events in the human and primate dpoamine D5 receptor gene family," <i>Gene</i> , 154:153-158 (March 10, 1995)
CG	MILLS, et al., "Orphan Seven Transmembrane Domain Receptors Reversing Pharmacology," <i>Trends in Pharmacological Sci.</i> , 14(11):394-396 (1993)
CH	PEYRON, et al., "A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains," <i>Nature Medicine</i> , 6(9):991-7 (September 2000)
CI	PROBST, et al., "Sequence alignment of the G-protein coupled receptor superfamily," <i>DNA and Cell Biology</i> , 11:1-20 (1992)
CJ	RINK, "In search of a satiety factor," <i>Nature</i> , 372:406-407 (1994)
CK	SAKURAI, et al., "Orexins and orexin receptor: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior," <i>Cell</i> , 92:573-585 (1998)
CL	TARTAGLIA, et al., "Identification and expression cloning of a leptin receptor, OB-R," <i>Cell</i> , 83:1263-1271 (1995)
CM	VOISIN, et al., "Orexins and their receptors: structural aspects and role in peripheral tissues," <i>Cell. Mol. Life Sci.</i> , 60:72-87 (January 2003)
CN	WELCH, et al., "Sequence and tissue distribution of a candidate G-coupled receptor cloned from rat hypothalamus," <i>Biochem. Biophys. Res. Commun.</i> , 209(2):606-613 (April 17, 1995)
CO	WILLIE, et al., "To eat or sleep? Orexin in the regulation of feeding and wakefulness," <i>Ann Rev Neurosci</i> , 24:429-458 (2001)
CP	YAN, et al., "Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors," <i>PNAS</i> , 93:4661-4665 (1996)
CQ	YANG-FENG, et al., "Chromosomal organization of adrenergic receptor genes," <i>Proc. Natl. Acad. Sci. USA</i> , 87:1516-1520 (February 1990)
CR	ZHANG, et al., "Positional cloning of the mouse obese gene and its human homologue," <i>Nature</i> , 372:425-432 (December 1, 1994)
CS	ZHANG, et al., "Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons," <i>Proc. Natl. Acad. Sci. USA</i> , 91:11738-11742 (November 1994)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/13/04
--------------------	--	-----------------	----------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/070,532
				Filing Date	March 7, 2002
				First Named Inventor	Daniel R. Soppet
				Art Unit	1647
				Examiner Name	C. J. Nichols
Sheet	1	of	1	Attorney Docket Number	PF168P3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	CT	FRIEDMAN, et al., "Tackling a weighty problem," <i>Cell</i> , 69(2):217-220 (April 17, 1992)	
CS	CU	LOPEZ, et al., "Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus," <i>Biochem. Biophys. Res. Commun.</i> , 269(1):41-45 (March 5, 2000)	
CS	CV	SAHU, et al., "Nutritional regulation of hypothalamic leptin receptor gene expression is defective in diet-induced obesity," <i>J. Neuroendocrinol.</i> , 14(11):887-893 (November 2002); Erratum in: <i>J. Neuroendocrinol.</i> 15(1):104 (January 2003)	
CS	CW	SMITH, et al., "Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat," <i>Neurosci Lett.</i> , 341(3):256-258 (May 8, 2003)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/23/04
--------------------	---	-----------------	----------